CommercialCoverageMedium impact
08.00.82q, Ustekinumab for Intravenous Infusion
Independence Blue Cross·Pharmacy, Rheumatology, Gastroenterology +1 more·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Policy 08.00.82q for Ustekinumab intravenous infusion has been updated effective July 1, 2026. This is a commercial pharmacy policy update that may affect coverage criteria, prior authorization requirements, or reimbursement for IV ustekinumab administration. The billing team must review the full policy details to identify specific changes to claims processing.
Action Required
By June 15, 2026: Billing team and clinical staff must obtain and review the complete Policy 08.00.82q text from the source URL to identify specific coverage changes, prior authorization requirements, and billing code updates for ustekinumab IV infusion. Update billing system rules, prior authorization workflows, and provider communication materials accordingly. On or before July 1, 2026, ensure all staff are trained on new requirements. Failure to implement changes may result in claim denials for ustekinumab IV infusion claims submitted on or after the effective date.